Page 1826 - Williams Hematology ( PDFDrive )

1800 Part XI: Malignant Lymphoid Diseases Chapter 109: Macroglobulinemia 1801

180. Treon SP, Tripsas CK, Meid K, et al: Ibrutinib in previously treated Waldenstrom’s Mac- 190. Varghese AM, Rawstron AC, Ashcroft J, et al: Assessment of bone marrow response in
roglobulinemia. N Engl J Med 372(15):1430, 2015. Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma 9:53, 2009.
181. Ghobrial IM, Witzig TE, Gertz M, et al: Long-term results of the phase II trial of the 191. Ciccarelli BT, Yang G, Hatjiharissi E, et al: Soluble CD27 is a faithful marker of disease
oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenström burden and is unaffected by the rituximab induced IgM flare, as well as plasmaphere-
macroglobulinemia. Am J Hematol; 89:237, 2014. sis in patients with Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma 9:56,
182. Treon SP, Tripsas CK, Meid K, et al: Prospective, multicenter study of the mTOR inhib- 2009.
itor everolimus (RAD001) as primary therapy in Waldenström’s macroglobulinemia. 192. Gobbi PG, Bettini R, Montecucco C, et al: Study of prognosis in Waldenström’s macro-
Blood 2013; 122:1822. globulinemia: A proposal for a simple binary classification with clinical and investiga-
183. Treon SP, Hanzis, C, Manning, RJ, et al: Maintenance rituximab is associated with tional utility. Blood 83:2939, 1994.
improved clinical outcome in rituximab naïve patients with Waldenström’s macro- 193. Morel P, Monconduit M, Jacomy D, et al: Prognostic factors in Waldenström macro-
globulinemia who respond to a rituximab containing regimen. Br J Haematol 2011; globulinemia: A report on 232 patients with the description of a new scoring system
154:357–62. and its validation on 253 other patients. Blood 96:852, 2000.
184. Rummel MJ, Lerchenmüller C, Greil R, et al: Bendamustine-rituximab induction fol- 194. Dhodapkar MV, Jacobson JL, Gertz MA, et al: Prognostic factors and response to flu-
lowed by observation or rituximab maintenance for newly diagnosed patients with darabine therapy in patients with Waldenström macroglobulinemia: Results of United
Waldenström’s macroglobulinemia: results from a prospective, randomized, multicen- States intergroup trial (Southwest Oncology Group S9003). Blood 98:41, 2001.
ter study (StiL NHL 7–2008). Blood 2012; 120: 2739. 195. Dimopoulos M, Gika D, Zervas K, et al: The international staging system for multi-
185. Kyriakou C, Canals C, Sibon D, et al: High-dose therapy and autologous stem-cell ple myeloma is applicable in symptomatic Waldenström’s macroglobulinemia. Leuk
transplantation in Waldenström macroglobulinemia: The Lymphoma Working Party Lymphoma 45:1809, 2004.
of the European Group for Blood and Marrow Transplantation. J Clin Oncol 28:2227, 196. Anagnostopoulos A, Zervas K, Kyrtsonis M, et al: Prognostic value of serum beta
2010. 2-microglobulin in patients with Waldenström’s macroglobulinemia requiring therapy.
186. Kyriakou C, Canals C, Cornelissen JJ, et al: Allogeneic stem-cell transplantation in Clin Lymphoma Myeloma 7:205, 2006.
patients with Waldenström macroglobulinemia: report from the Lymphoma Work- 197. Morel P, Duhamel A, Gobbi P, et al: International prognostic scoring system for Wal-
ing Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol denström macroglobulinemia. Blood 113:4163, 2009.
28:4926, 2010. 198. Castillo JJ, Olszewski A, Cronin AM, et al: Survival trends in Waldenström macro-
187. Owen RG, Kyle RA, Stone MJ, et al: Response Assessment in Waldenström macroglob- globulinemia: An analysis of the Surveillance, Epidemiology and End Results database.
ulinemia. Br J Haematol 160:171, 2013. Blood 123:3999, 2014.
188. Treon SP, Yang G, Hanzis C, et al: Attainment of complete/very good partial response 199. Kastritis S, Kyrtsonis MC, Hatjiharissi E, et al: No significant improvement in the out-
following rituximab based therapy is an important determinant to progression-free come of patients with Waldenström macroglobulinemia treated over the last 25 years.
survival and is impacted by polymorphisms in FCGR3A in Waldenström macroglobu- Am J Hematol 86:479, 2011.
linaemia. Br J Haematol 154:223, 2011. 200. Kristinsson SY, Eloranta S, Dickman PW, et al: Patterns of survival in lymphoplasma-
189. Strauss SJ, Maharaj L, Hoare S, et al: Bortezomib therapy in patients with relapsed or cytic lymphoma/Waldenström macroglobulinemia: a population based study of 1,555
refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis patients diagnosed in Sweden from 1980 to 2005. Am J Hematol 88:60, 2013.
factor alpha response with clinical activity. J Clin Oncol 24:2105, 2006.

Kaushansky_chapter 109_p1785-1802.indd 1801 9/21/15 12:31 PM